To study whether a drug (Saroglitazaar) used to treat diabetes and deranged lipid profile can lead to improvement in fatty liver also
Not Applicable
Completed
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2019/05/019199
- Lead Sponsor
- Dept of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 107
Inclusion Criteria
1.Age between 18-70 years
2.Diabetes and Dyslipidemia requiring medical treatment
Exclusion Criteria
1.Chronic viral hepatitis
2.Significnt alcohol intake
3.Uncontrolled thyroid disease
4.Active cardio-pulmonary disease.
5.Current/past history of malignancy.
6.Chronic liver disease or chronic kidney disease (CKD).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect of Saroglitazar on liver enzymes in patients with diabetic dyslipidemia.Timepoint: 24 weeks
- Secondary Outcome Measures
Name Time Method Effect of Saroglitazaar on transient elastographyTimepoint: 24 weeks